Nestlé Health Science announced today that it will make an investment of USD 145 million in Aimmune Therapeutics, based in Brisbane (California, USA). The collaboration will accelerate the development of therapies for people with food allergies, including peanut allergy sufferers.
Food allergies have a huge personal impact and are an economic burden, affecting between 5-8% of children and 1-2% of adults. The investment is part of Nestlé Health Science’s commitment to innovation in the management of food allergies and building a broad portfolio of solutions for patients.
Aimmune is developing treatments for life-threatening food allergies, to desensitise and protect patients from the consequences of accidental exposure. Aimmune’s lead product AR101 is in Phase III trial for peanut allergy, with US FDA Breakthrough Therapy Designation.
Nestlé Health Science already has an established portfolio of nutritional solutions for pediatric food allergy and intolerances, especially Cow’s Milk Protein Allergy (CMPA).
Read the press release on Nestlé Health Science's website